Siegfried’s DINAMIQS Wins Swissmedic License, Expanding Viral Vector CDMO Capabilities

Siegfried Holding AG ( (CH:SFZN) ) has shared an announcement.

DINAMIQS, a Siegfried company specializing in viral vector CDMO services, has obtained a Swissmedic license for cGMP-compliant manufacturing and testing of viral vectors, enabling the production and release of genomic medicines under full regulatory oversight. The new 2,500 m² Zurich facility integrates process development, drug substance production, aseptic fill-finish and quality control, aiming to cut complexity, timelines and tech-transfer risks while supporting efficient regulatory pathways through Switzerland’s recognition agreements with European and U.S. authorities.

With more than 300 batches of Adeno-Associated and Lentiviral vectors already produced and first runs from the new plant showing best-in-class yields and quality, DINAMIQS is positioned as a fully integrated partner for gene therapy developers. This approval significantly enhances Siegfried’s presence in the fast-growing cell and gene therapy market, reinforcing its strategic push into advanced therapies and broadening its appeal to both large and emerging biopharma customers seeking global market access for next-generation treatments.

The most recent analyst rating on (CH:SFZN) stock is a Hold with a CHF85.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.

More about Siegfried Holding AG

Siegfried Holding AG is a global Contract Development and Manufacturing Organization (CDMO) with sites across Europe, the U.S. and China, generating CHF 1,327.8 million in sales in 2025 and employing more than 3,800 people. The group manufactures pharmaceutical active ingredients and intermediates as well as finished dosage forms such as tablets, capsules and sterile injectables, and provides development services to pharmaceutical companies worldwide.

Average Trading Volume: 111,192

Technical Sentiment Signal: Sell

Current Market Cap: CHF3.52B

For an in-depth examination of SFZN stock, go to TipRanks’ Overview page.